Wen Shi-Wang, Han Li, Lv Hui-Lai, Xu Yan-Zhao, Li Zhen-Hua, Wang Ming-Bo, Zhu Yong-Gang, Su Peng, Tian Zi-Qiang, Zhang Yue-Feng
a Department of Thoracic Surgery , The Forth Hospital of Hebei Medical University , Shijiazhuang , China.
b Department of Emergency , The Forth Hospital of Hebei Medical University , Shijiazhuang , China.
J Invest Surg. 2019 Jan;32(1):27-34. doi: 10.1080/08941939.2017.1370519. Epub 2017 Oct 6.
The aim of this study was to compare the efficacy between SBRT and surgery based on the Propensity-Matched Analysis.
Publications on comparison SBRT and Surgery for early stage non- small cell lung cancer (NSCLC) from 2011 to 2017 were collected. Propensity score matching was used to achieve comparable treatment hazard ratios of the overall survival (OS), local control survival (LC), regional control survival (RC), loco-regional control survival (LRC), distant control survival (DC), disease-free survival (DFS), and progression-free survival (PFS) between SBRT and Surgery. The major outcomes measures were hazard ratios (HRs). Meta-analysis Revman 5.3 software was used to analyze the combined Pooled HRs using fixed- or random-effects models according to the heterogeneity.
Eleven studies met our inclusion criteria. The LC, L-R C, DC, DFS and PFS rates of patients with early-stage lung cancer who were treated with SBRT are equal to surgical results. While, patients with surgery achieved superior OS compared with SBRT.
In this study we carried out a meta-analysis, which controls the acceptable level of the efficacy in the propensity score to match patients. The surgery had obvious OS advantages in this meta-analysis. However, these conclusions would be proven by further studies incorporating comorbidity data, and outcomes from randomized control study. The final decision for the optimal treatment of a patient with early-stage NSCLC can be substantiated by a personalized treatment model.
本研究旨在基于倾向匹配分析比较立体定向体部放疗(SBRT)与手术的疗效。
收集2011年至2017年比较SBRT与手术治疗早期非小细胞肺癌(NSCLC)的文献。采用倾向评分匹配法,以实现SBRT与手术在总生存(OS)、局部控制生存(LC)、区域控制生存(RC)、局部区域控制生存(LRC)、远处控制生存(DC)、无病生存(DFS)和无进展生存(PFS)方面具有可比的治疗风险比。主要结局指标为风险比(HRs)。使用Meta分析Revman 5.3软件,根据异质性采用固定效应或随机效应模型分析合并的汇总HRs。
11项研究符合纳入标准。接受SBRT治疗的早期肺癌患者的LC、L-R C、DC、DFS和PFS率与手术结果相当。然而,接受手术的患者与SBRT相比,OS更优。
在本研究中,我们进行了一项荟萃分析,该分析在倾向评分中控制了患者疗效的可接受水平。在这项荟萃分析中,手术具有明显的OS优势。然而,这些结论将通过纳入合并症数据的进一步研究以及随机对照研究的结果得到证实。早期NSCLC患者最佳治疗的最终决策可通过个性化治疗模型得到证实。